companies / gedeabiotech-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-02 json
| total_raised | 6,150,0006.2M | ○ |
|---|---|---|
| founded | 2015 | |
| hq | Lund, Sweden | |
| industry | unknown | |
| stage | null |
Gedea Biotech develops pHyph, an antibiotic-free vaginal tablet that treats and prevents bacterial vaginosis by strengthening the vaginal microbiome. It is built for women suffering recurrent bacterial vaginosis and the clinicians treating them. Its trial data show 100 percent symptom-free patients at day 35 versus 54 to 77 percent for antibiotics, spun out of Lund University.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2024-04-01 | grant | 2,700,0002.7M | null | ○ |
LiteSpeed, PHP 8.1.34, WordPress 7.0, Yoast SEO 27.5, Google Tag Manager, jQuery Migrate 3.4.1, PrestaShop, Zepto, WP Rocket, MailChimp, Python, MySQL
| fact | status | src |
|---|---|---|
| Grant, $2.7M | attributed | ○ |
| existence | sourced | WEB |
| description | self-reported | WEB |
| date | fact | change | src |
|---|---|---|---|
| 2026-10-17provenance_existence: self-reported → sourced, WEB 2026-10-17 | provenance_existence | self-reported → sourced | WEB 2026-10-17 |
Records begin 2026-09-24. all_changes